1Jones RN, Croco MA, Pfaller MA, et al. Antimicrobial activity evaluation of gatifloxacin, a new fluoroquinolone:comtemporary pathogen results from a global antimicrobial resistance surveillance program(SENTRY, 1997)[J]. Clin Microbiol Infect, 1999, 5: 540-546
2Jones RN, Johnson DM, Erwin ME, et al. Antistreptococcal activity of gatifloxacin[J]. Drugs, 1999, 58 (suppl.2): 164-165
3Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin[J]. J Antimicrob Chemother, 1997, 40: 639-651
4Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy[J]. J Antimicrob Chemother, 2001, 47: 129-140
5Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection[J]. Curr Infect Dis Rep, 2001, 3: 29～34
7Ramirez JR, Nguyen TH, Tellier GT, et al. A prospective, randomized, double-blind, comparative study. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin[J]. J Respir Dis, 1999, 20: S40-48
8Sullivan JG, McElroy AD, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999, 20: S49-59
9Appelbaum PC. Quinolone activity against anaerobes[J]. Drugs, 1999, 58(suppl.2): 60-64
